EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Aggressive resection of non-contrast-enhanced tumor provides varying benefits to glioblastoma, IDH-wildtype patients based on different clinical characteristics

Lingyu Liu, Chihyi Liao, Siqi Ge, Xing Liu, Jiahan Dong, Shimeng Weng, Guoshi Huang, Zhong Zhang, Qiang Jin, Jiangwei Wang, Xing Fan, Ke-Nan Zhang und 1 weitere

Cancer Letters · 2025-03 · 612 · 217471

DOI: 10.1016/j.canlet.2025.217471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025-03. Verfasst von Lingyu Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioblastoma, Isocitrate Dehydrogenase, Brain Neoplasms, Neurosurgical Procedures. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Health Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Supramaximal resection in glioblastoma, concerning non-contrast-enhancing (nCE) tumors, exhibited additional survival benefits. However, whether all patients can benefit from supramaximal resection of nCE tumors and the optimal resection target remains unclear, especially for the glioblastoma, IDH-wildtype under the new WHO CNS tumor classification. Clinical and surgical characteristics were collected from 155 patients with newly diagnosed glioblastoma, IDH-wildtype from the Chinese Glioma Genome Atlas, and a prospective cohort of 128 patients was enrolled for external validation. Recursive partitioning analysis was used to identify risk groups considering the effects of residual nCE tumor volume (RnTV) and clinical factors on overall survival (OS). Age, preoperative Karnofsky Performance Score (KPS), MGMT promoter status, and postoperative RnTV were independently associated with patient survival. Four risk groups with distinct prognoses were identified: Group 1 (median OS: 13.4 months), RnTV >43.27 ml; Group 2 (median OS: 17.8 months), RnTV ≤43.27 ml, KPS ≤90, and age ≥60; Group 3 (median OS: 22.3 months), RnTV 5.27-43.27 ml, age

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaIsocitrate DehydrogenaseBrain NeoplasmsNeurosurgical ProceduresHumansFemaleMaleMiddle AgedAgedAdultProspective StudiesPrognosisDNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsKarnofsky Performance StatusPromoter Regions, GeneticTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

Clinical characteristicsGlioblastomaNon-contrast-enhancing tumorSupramaximal resectionSurvival

Substanzen

Isocitrate DehydrogenaseDNA Repair EnzymesMGMT protein, humanDNA Modification MethylasesTumor Suppressor ProteinsIDH1 protein, human

Autor:innen und Institutionen

  • Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Department of Neuropathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Neuroelectrophysiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: xingkongyaoxiang@163.com.
  • Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Electronic address: zhangkn3@ccmu.edu.cn.

Förderung

  • Beijing Municipal Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Liu, L., Liao, C., Ge, S., Liu, X., Dong, J., Weng, S., Huang, G., Zhang, Z., Jin, Q., Wang, J., Fan, X., Zhang, K. N., & Jiang, T. (2025). Aggressive resection of non-contrast-enhanced tumor provides varying benefits to glioblastoma, IDH-wildtype patients based on different clinical characteristics. Cancer Letters, 612, 217471. https://doi.org/10.1016/j.canlet.2025.217471

Vancouver

Liu L, Liao C, Ge S, Liu X, Dong J, Weng S, et al. Aggressive resection of non-contrast-enhanced tumor provides varying benefits to glioblastoma, IDH-wildtype patients based on different clinical characteristics. Cancer Letters. 2025;612:217471. doi:10.1016/j.canlet.2025.217471

BibTeX
@article{Liu2025,
  author = {Liu, Lingyu and Liao, Chihyi and Ge, Siqi and Liu, Xing and Dong, Jiahan and Weng, Shimeng and Huang, Guoshi and Zhang, Zhong and Jin, Qiang and Wang, Jiangwei and Fan, Xing and Zhang, Ke-Nan and Jiang, Tao},
  title = {Aggressive resection of non-contrast-enhanced tumor provides varying benefits to glioblastoma, IDH-wildtype patients based on different clinical characteristics},
  journal = {Cancer Letters},
  year = {2025},
  volume = {612},
  pages = {217471},
  doi = {10.1016/j.canlet.2025.217471}
}
Kostenlos starten →